A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy

Abstract A 73‐year‐old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) acti...

Full description

Bibliographic Details
Main Authors: Yuki Haruta, Masanori Azuma, Toshikatsu Sado, Ryuichi Saito, Yoshimune Miyazaki, Akihiro Noda, Reina Kitagawa, Yasutaka Hori, Sayaka Fujimoto, Yoshinori Hasegawa, Tetsuya Ueda, Ryosuke Yamamura
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Respirology Case Reports
Subjects:
haemophilia
factor V inhibitors
hem‐irAE
immune checkpoint inhibitors
Online Access:https://doi.org/10.1002/rcr2.1307

Internet

https://doi.org/10.1002/rcr2.1307

Similar Items